Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Discovery and optimization of a series of sulfonamide inverse agonists for the retinoic acid receptor-related receptor-α.

Doebelin C, He Y, Campbell S, Nuhant P, Kumar N, Koenig M, Garcia-Ordonez R, Chang MR, Roush WR, Lin L, Kahn S, Cameron MD, Griffin PR, Solt LA, Kamenecka TM.

Med Chem. 2019 Feb 22. doi: 10.2174/1573406415666190222124745. [Epub ahead of print]

PMID:
30799793
2.

REV-ERBα Regulates TH17 Cell Development and Autoimmunity.

Amir M, Chaudhari S, Wang R, Campbell S, Mosure SA, Chopp LB, Lu Q, Shang J, Pelletier OB, He Y, Doebelin C, Cameron MD, Kojetin DJ, Kamenecka TM, Solt LA.

Cell Rep. 2018 Dec 26;25(13):3733-3749.e8. doi: 10.1016/j.celrep.2018.11.101.

3.

Identification of potent RORβ modulators: Scaffold variation.

Doebelin C, Patouret R, Garcia-Ordonez RD, Chang MR, Dharmarajan V, Novick S, Ciesla A, Campbell S, Solt LA, Griffin PR, Kamenecka TM.

Bioorg Med Chem Lett. 2018 Oct 15;28(19):3210-3215. doi: 10.1016/j.bmcl.2018.08.017. Epub 2018 Aug 16.

PMID:
30143422
4.

Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation.

Zhao J, Zhang L, Mu X, Doebelin C, Nguyen W, Wallace C, Reay DP, McGowan SJ, Corbo L, Clemens PR, Wilson GM, Watkins SC, Solt LA, Cameron MD, Huard J, Niedernhofer LJ, Kamenecka TM, Robbins PD.

PLoS Biol. 2018 Jun 11;16(6):e2004663. doi: 10.1371/journal.pbio.2004663. eCollection 2018 Jun.

5.

Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle.

Amador A, Campbell S, Kazantzis M, Lan G, Burris TP, Solt LA.

PLoS One. 2018 May 3;13(5):e0196787. doi: 10.1371/journal.pone.0196787. eCollection 2018.

6.

REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009.

Amador A, Kamenecka TM, Solt LA, Burris TP.

Biochem Pharmacol. 2018 Apr;150:1-8. doi: 10.1016/j.bcp.2018.01.009. Epub 2018 Jan 23.

PMID:
29355503
7.

RORα modulates semaphorin 3E transcription and neurovascular interaction in pathological retinal angiogenesis.

Sun Y, Liu CH, Wang Z, Meng SS, Burnim SB, SanGiovanni JP, Kamenecka TM, Solt LA, Chen J.

FASEB J. 2017 Oct;31(10):4492-4502. doi: 10.1096/fj.201700172R. Epub 2017 Jun 23.

8.

Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.

Amador A, Huitron-Resendiz S, Roberts AJ, Kamenecka TM, Solt LA, Burris TP.

PLoS One. 2016 Sep 7;11(9):e0162452. doi: 10.1371/journal.pone.0162452. eCollection 2016.

9.

Correction: Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.

Amador A, Wang Y, Banerjee S, Kamenecka TM, Solt LA, Burris TP.

PLoS One. 2016 May 19;11(5):e0156367. doi: 10.1371/journal.pone.0156367. eCollection 2016.

10.

Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nurr1.

de Vera IM, Giri PK, Munoz-Tello P, Brust R, Fuhrmann J, Matta-Camacho E, Shang J, Campbell S, Wilson HD, Granados J, Gardner WJ Jr, Creamer TP, Solt LA, Kojetin DJ.

ACS Chem Biol. 2016 Jul 15;11(7):1795-9. doi: 10.1021/acschembio.6b00037. Epub 2016 Apr 29.

11.

Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.

Amador A, Wang Y, Banerjee S, Kameneka TM, Solt LA, Burris TP.

PLoS One. 2016 Mar 10;11(3):e0151014. doi: 10.1371/journal.pone.0151014. eCollection 2016. Erratum in: PLoS One. 2016;11(5):e0156367.

12.

Metabolism of murine TH 17 cells: Impact on cell fate and function.

Wang R, Solt LA.

Eur J Immunol. 2016 Apr;46(4):807-16. doi: 10.1002/eji.201545788. Epub 2016 Mar 10. Review.

13.

Nuclear receptor RORα regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation.

Sun Y, Liu CH, SanGiovanni JP, Evans LP, Tian KT, Zhang B, Stahl A, Pu WT, Kamenecka TM, Solt LA, Chen J.

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10401-6. doi: 10.1073/pnas.1504387112. Epub 2015 Aug 4.

14.

Th17 cells in Type 1 diabetes: a future perspective.

Solt LA, Burris TP.

Diabetes Manag (Lond). 2015 Jul;5(4):247-250. No abstract available.

15.

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP.

Cancer Cell. 2015 Jul 13;28(1):42-56. doi: 10.1016/j.ccell.2015.05.007. Epub 2015 Jun 25.

16.

Suppression of atherosclerosis by synthetic REV-ERB agonist.

Sitaula S, Billon C, Kamenecka TM, Solt LA, Burris TP.

Biochem Biophys Res Commun. 2015 May 8;460(3):566-71. doi: 10.1016/j.bbrc.2015.03.070. Epub 2015 Mar 20.

17.

ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes.

Solt LA, Banerjee S, Campbell S, Kamenecka TM, Burris TP.

Endocrinology. 2015 Mar;156(3):869-81. doi: 10.1210/en.2014-1677. Epub 2015 Jan 5.

18.

Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour.

Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, Burris TP.

Nat Commun. 2014 Dec 23;5:5759. doi: 10.1038/ncomms6759.

19.

Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonist.

Matta-Camacho E, Banerjee S, Hughes TS, Solt LA, Wang Y, Burris TP, Kojetin DJ.

J Biol Chem. 2014 Jul 18;289(29):20054-66. doi: 10.1074/jbc.M113.545111. Epub 2014 May 28.

20.

Noncanonical NF-κB signaling is limited by classical NF-κB activity.

Gray CM, Remouchamps C, McCorkell KA, Solt LA, Dejardin E, Orange JS, May MJ.

Sci Signal. 2014 Feb 4;7(311):ra13. doi: 10.1126/scisignal.2004557.

21.

Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy.

Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, Hesselink MK, Paquet C, Delhaye S, Shin Y, Kamenecka TM, Schaart G, Lefebvre P, Nevière R, Burris TP, Schrauwen P, Staels B, Duez H.

Nat Med. 2013 Aug;19(8):1039-46. doi: 10.1038/nm.3213. Epub 2013 Jul 14.

22.

Identification of a novel selective inverse agonist probe and analogs for the Retinoic acid receptor-related Orphan Receptor Alpha (RORα).

Kumar N, Nuhant P, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Ruben DGO, Burris TP, Cameron M, Mercer BA, Hodder P, Roush WR, Rosen H, Griffin PR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Sep 1 [updated 2013 Mar 14].

23.

Nuclear receptors and their selective pharmacologic modulators.

Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, Kojetin DJ.

Pharmacol Rev. 2013 Mar 1;65(2):710-78. doi: 10.1124/pr.112.006833. Print 2013 Apr. Review.

PMID:
23457206
24.

A liver-selective LXR inverse agonist that suppresses hepatic steatosis.

Griffett K, Solt LA, El-Gendy Bel-D, Kamenecka TM, Burris TP.

ACS Chem Biol. 2013 Mar 15;8(3):559-67. doi: 10.1021/cb300541g. Epub 2012 Dec 27.

PMID:
23237488
25.

LXR-mediated inhibition of CD4+ T helper cells.

Solt LA, Kamenecka TM, Burris TP.

PLoS One. 2012;7(9):e46615. doi: 10.1371/journal.pone.0046615. Epub 2012 Sep 28.

26.

Action of RORs and their ligands in (patho)physiology.

Solt LA, Burris TP.

Trends Endocrinol Metab. 2012 Dec;23(12):619-27. doi: 10.1016/j.tem.2012.05.012. Epub 2012 Jul 11. Review.

27.

Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells.

Solt LA, Kumar N, He Y, Kamenecka TM, Griffin PR, Burris TP.

ACS Chem Biol. 2012 Sep 21;7(9):1515-9. Epub 2012 Jul 9.

28.

Regulation of p53 stability and apoptosis by a ROR agonist.

Wang Y, Solt LA, Kojetin DJ, Burris TP.

PLoS One. 2012;7(4):e34921. doi: 10.1371/journal.pone.0034921. Epub 2012 Apr 11.

29.

Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.

Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP.

Nature. 2012 Mar 29;485(7396):62-8. doi: 10.1038/nature11030.

30.

Identification of SR2211: a potent synthetic RORγ-selective modulator.

Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, Griffin PR.

ACS Chem Biol. 2012 Apr 20;7(4):672-7. doi: 10.1021/cb200496y. Epub 2012 Feb 13.

31.

Structural and biophysical insights into the ligand-free Pitx2 homeodomain and a ring dermoid of the cornea inducing homeodomain mutant.

Doerdelmann T, Kojetin DJ, Baird-Titus JM, Solt LA, Burris TP, Rance M.

Biochemistry. 2012 Jan 17;51(2):665-76. doi: 10.1021/bi201639x. Epub 2012 Jan 6.

32.

Genetic dissection of the functions of the melanocortin-3 receptor, a seven-transmembrane G-protein-coupled receptor, suggests roles for central and peripheral receptors in energy homeostasis.

Begriche K, Levasseur PR, Zhang J, Rossi J, Skorupa D, Solt LA, Young B, Burris TP, Marks DL, Mynatt RL, Butler AA.

J Biol Chem. 2011 Nov 25;286(47):40771-81. doi: 10.1074/jbc.M111.278374. Epub 2011 Oct 7.

33.

Campaign to identify novel modulators of the Retinoic acid receptor-related Orphan Receptors (ROR).

Kumar N, Solt LA, Conkright J, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez RD, Nuhant P, Burris T, Mercer BA, Hodder P, Roush WR, Rosen H, Griffin PR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2009 Jan 3 [updated 2011 Mar 11].

34.

The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis.

Solt LA, Kojetin DJ, Burris TP.

Future Med Chem. 2011 Apr;3(5):623-38. doi: 10.4155/fmc.11.9. Review.

35.

Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand.

Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidović D, Schürer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP.

Nature. 2011 Apr 28;472(7344):491-4. doi: 10.1038/nature10075. Epub 2011 Apr 17.

36.

Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist.

Kumar N, Kojetin DJ, Solt LA, Kumar KG, Nuhant P, Duckett DR, Cameron MD, Butler AA, Roush WR, Griffin PR, Burris TP.

ACS Chem Biol. 2011 Mar 18;6(3):218-22. doi: 10.1021/cb1002762. Epub 2010 Dec 6.

37.

Cutting edge: association with I kappa B kinase beta regulates the subcellular localization of Homer3.

Yatherajam G, Banerjee PP, McCorkell KA, Solt LA, Hanson EP, Madge LA, Kang S, Worley PF, Orange JS, May MJ.

J Immunol. 2010 Sep 1;185(5):2665-9. doi: 10.4049/jimmunol.0903488. Epub 2010 Aug 6.

38.

Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics.

Solt LA, Griffin PR, Burris TP.

Curr Opin Lipidol. 2010 Jun;21(3):204-11. doi: 10.1097/MOL.0b013e328338ca18. Review.

39.

Regulation of adipogenesis by natural and synthetic REV-ERB ligands.

Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, Kamenecka TM, Stayrook KR, Crumbley C, Floyd ZE, Gimble JM, Griffin PR, Burris TP.

Endocrinology. 2010 Jul;151(7):3015-25. doi: 10.1210/en.2009-0800. Epub 2010 Apr 28.

40.

Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor alpha.

Wang Y, Solt LA, Burris TP.

J Biol Chem. 2010 May 21;285(21):15668-73. doi: 10.1074/jbc.M110.102160. Epub 2010 Mar 23.

41.

Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands.

Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordonez RD, Stayrook KR, Zhang X, Novick S, Chalmers MJ, Griffin PR, Burris TP.

J Biol Chem. 2010 Feb 12;285(7):5013-25. doi: 10.1074/jbc.M109.080614. Epub 2009 Dec 4.

42.

The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist.

Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez RD, Burris TP, Griffin PR.

Mol Pharmacol. 2010 Feb;77(2):228-36. doi: 10.1124/mol.109.060905. Epub 2009 Nov 3.

43.

NEMO-binding domains of both IKKalpha and IKKbeta regulate IkappaB kinase complex assembly and classical NF-kappaB activation.

Solt LA, Madge LA, May MJ.

J Biol Chem. 2009 Oct 2;284(40):27596-608. doi: 10.1074/jbc.M109.047563. Epub 2009 Aug 7.

44.

Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity.

Hanson EP, Monaco-Shawver L, Solt LA, Madge LA, Banerjee PP, May MJ, Orange JS.

J Allergy Clin Immunol. 2008 Dec;122(6):1169-1177.e16. doi: 10.1016/j.jaci.2008.08.018. Epub 2008 Oct 11.

45.

The IkappaB kinase complex: master regulator of NF-kappaB signaling.

Solt LA, May MJ.

Immunol Res. 2008;42(1-3):3-18. doi: 10.1007/s12026-008-8025-1. Review.

46.

G protein-coupled receptor Ca2+-linked mitochondrial reactive oxygen species are essential for endothelial/leukocyte adherence.

Hawkins BJ, Solt LA, Chowdhury I, Kazi AS, Abid MR, Aird WC, May MJ, Foskett JK, Madesh M.

Mol Cell Biol. 2007 Nov;27(21):7582-93. Epub 2007 Aug 27.

47.

Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta.

Solt LA, Madge LA, Orange JS, May MJ.

J Biol Chem. 2007 Mar 23;282(12):8724-33. Epub 2007 Jan 23.

48.

BCR engagement induces Fas resistance in primary B cells in the absence of functional Bruton's tyrosine kinase.

Tumang JR, Negm RS, Solt LA, Schneider TJ, Colarusso TP, Hastings WD, Woodland RT, Rothstein TL.

J Immunol. 2002 Mar 15;168(6):2712-9.

49.

Splenic and peritoneal B-1 cells differ in terms of transcriptional and proliferative features that separate peritoneal B-1 from splenic B-2 cells.

Fischer GM, Solt LA, Hastings WD, Yang K, Gerstein RM, Nikolajczyk BS, Clarke SH, Rothstein TL.

Cell Immunol. 2001 Oct 10;213(1):62-71.

PMID:
11747357

Supplemental Content

Support Center